Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma

Surgical Neurology

Volumn 53, Issue 4, 2000, Pages 360-369

  Julien, Terrence ^a   Frankel, Bruce ^a   Longo, Sharon ^a   Kyle, Michele ^a   Gibson, Sandra ^b   Shillitoe, Edward ^b   Ryken, Timothy ^c  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Apoptosis; bcl 2; Gene therapy; Glioma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; FEMALE; FIBROBLAST; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; ONCOGENE;

AGED; APOPTOSIS; BRAIN NEOPLASMS; CELL SURVIVAL; CODON, NONSENSE; DNA, NEOPLASM; FEMALE; GENE EXPRESSION; GLIOMA; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; POINT MUTATION; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034068054     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-3019(00)00178-6     Document Type: Article

References (36)

1. Artificial Regulation of Gene Expression by Complimentary Oligonucleotides-An Overview. Antisense RNA and DNA 1994;175-194.
2. Anker L., Ohgaki H., Ludeke B.I., Herrmann H.D., Kleihues P., Westphal M. p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer. 55:1993;982-987.
3. 2, and bax in neuroendocrine lung tumors. Am J Pathol. 149:1996;1941-1952.
4. Buchsbaum D.J., Raben D., Stackhouse M.A., Khazaeli M.B., Rogers B.E., Rosenfeld M.E., Liu T., Curiel D.T. Approaches to enhance cancer radiotherapy employing gene transfer methods. Gene Therapy. 3:1996;1042-1068.
5. Canute G.W., Longo S.L., Longo J.A., Winfield J.A., Nevaldine B.H., Hahn P.J. Hydroxyurea accelerates the loss of the epidermal growth factor receptor genes amplifies as double-minute chromosomes in human glioblastoma multiforme. Neurosurgery. 39:1996;976-983.
6. Cazenave C, Chevrier M, Thuong T, Helene C. Rate of degradation of [alpha-] and [beta-] oligodeoxynucleotides in Xenopus oocytes. Implications for anti-messenger strategies. Nucleic Acids Res 1987;10507-21.
7. Chinnaiyan A.M., Orth K., O'Rourke K., Duan H., Poirier G.G., Dixit V.M. Molecular Ordering of the Cell Death Pathway. J Biol Chem. 271:1996;4573-4576.
8. Cotter F.E., Johnson P., Hall P., Pocock C., Al Mahdi N., Cowell J.K., Morgan G. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene. 9:1994;3049-3055.
9. Davies A.M. The Bcl-2 family of proteins, and the regulation of neuronal survival. Trends Neurosci. 18:1995;355-358.
10. Ellison D.W., Steart P.V., Gatter K.C., Weller R.O. Apoptosis in cerebral astrocytic tumors and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol. 21:1995;352-361.
11. Ferrer I., Pozas E., López E., Ballabriga J. Bcl-2, Bax and Bcl-x expression following hypoxia-ischemia in the infant rat brain. Acta Neuropathol. 94:1997;583-589.
12. Goodchild J. Inhibition of gene expression by oligodeoxynucleotides. Oligodeoxynucleotides: antisense inhibitors of gene expression 1989:53-77.
13. Haeuptle M, Frank R, Dobberstein E. Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length. Nucleic Acids Res 1986:1427-48.
14. Han J., Sabbatini P., Perez D., Rao L., Modha D. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes and Dev. 10:1996;461-477.
15. Jansen B., Schlagbauer-Wadl H., Brown B.D., Bryan R.N., Van Elsas A., Müller M., Wolff K., Eichler H.G., Pehamberger H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med. 4:1998;232-234.
16. Kitada S., Miyashita T., Tanaka S., Reed J. Investigations of Antisense Oligonucleotides Targeted Against bcl-2 RNAs. Antisense Res Dev. 3:1993;157-169.
17. Loke S.L., Stein C.A., Zhang X., Mori K., Nakanishi M., Subasinghe C., Cohen J.S., Neckers L.M. Characterization of oligodeoxynucleotide transport into living cells. Proc Natl Acad Sci. 86:1989;3474-3478.
18. Miyashita T., Reed J.C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7. 2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 10-1-. 52:1992;5407-5411.
19. Miyashita T., Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemic cell line. Blood 1-1-. 81:1993;151-157.
20. Mustonen M., Raunio H., Pääkkö P., Soini Y. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology. 31:1997;347-354.
21. Neckers LM. Antisense oligodeoxynucleotides as a tool for studying cell regulation: mechanism of uptake and application to the study of oncogene function. Oligodeoxynucleotides. Antisense Inhib Gene Exp 1989:212-31.
22. Oltvai Z.N., Millman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax that accelerates programmed cell death. Cell. 74:1993;609-619.
23. Raynaud F., Orr R., Goddard P., Lacey H., Lancashire H., Judson I., Beck T., Bryan B., Cotter F.E. Pharmacokinetics of G3139, a Phosphorothioate Oligonucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice. J Pharmacol Exp Ther. 281:1997;420-427.
24. Reed J.C. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
25. Reed J.C., Cuddy M., Haldar S., Croce C.M., Nowell P., Makeover D., Bradley K. BCL2-mediated tumorgenicity of a human T-lymphoid cell line Synergy with MYC and inhibition by BCL2 Antisense . Proc Natl Acad Sci. 87:1990;3660-3664.
26. Reed J.C., Stein C., Subasinghe C., Haldar S., Croce C.M., Yum S., Cohen J. Antisense-mediated inhibition of BCL-2 protooncogene expression and leukemic cell growth and survival comparisons of phosphodiester and phosphorothioate oligonucleotides . Cancer Res. 50:1990;6565-6570.
27. Simonen M., Keller H., Heim J. The BH3 domain of Bax is sufficient for interaction of Bax with itself and with other family members and it is required for induction of apoptosis. Eur J Biochem. 249:1997;85-91.
28. Stein CA, Mori K, Loke SL, Subasinghe C, Shinozuka K, Cohen JA, Neckers LM. Phosphorothioate and normal oligodeoxynucleotides with 5′-linked acridine: characterization and preliminary kinetics of cellular uptake. Gene 1988:333-41.
29. Thompson C. Apoptosis in the pathogenesis and treatment of disease. Science 3-10-. 267:1995;1456-1462.
30. Tsujimoto Y., Cossman J., Jaffe E., Croce C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 228:1985;1440-1443.
31. Vogelbaum M.A., Tong J.X.X., Higashikubo R., Gutmann D.H., Rich K.M. Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. J Neurosurg. 88:1998;99-105.
32. Von Deimling A., Louis D.N., Wiestler O.D. Molecular Pathways in the Formation of Gliomas. Glia. 15:1995;328-338.
33. Webb A., Cunningham D., Cotter F.E., Stefano F., Ross P., Corbo M., Dziewanowska Z. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 4-19-. 349:1997;1137-1141.
34. Weller M., Malipiero U., Aguzzi A., Reed J.C., Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 95:1995;2633-2643.
35. Yin C., Knudson C.M., Korsmeyer S.J., Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 2-13-. 385:1997;637-640.
36. Zhan Q., Fan S., Insoo B., Guillouf C., Liebermann D., O'Connor P.M., Fornace A.J. Jr. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene. 9:1994;3743-3751.